Back To Search Instructions
Protocols
13 protocols meet the specified criteria
Disease Site: Ovary
Protocol No.TitleStatus
1200000138Biospecimen Repository for Individuals at High Risk for Breast, Ovarian, or Other Hereditary CancersOpen
1404299159Imaging of the ovary with a volume holographic imaging system: pilot studyOpen
1502660379S1316: Prospective Comparative Effectiveness Trial for Malignant Bowel ObstructionOpen
1504771536Continued Recruitment of High-Risk and Low-Risk control subjects to assess biomarkers of ovarian cancer riskOpen
1508036559A Multicentre Randomised Phase II Study of AZD1775 plus Chemotherapy versus Chemotherapy Alone in Patients with Platinum-Resistant TP53-Mutated Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerOpen
1511224935A Randomized, Open-Label Study Comparing the Combination of YONDELIS(R) and DOXIL(R) / CAELYX(R) With DOXIL(R) / CAELYX(R) Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerOpen
1602381312A PHASE 1A/B STUDY OF THE FOLIC ACID-TUBULYSIN CONJUGATE EC1456 IN PATIENTS WITH ADVANCED SOLID TUMORSOpen
1610935809A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyOpen
1612038226ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerOpen
1702240492A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerOpen
1703273335FOCUS: A Multicenter, Multinational, Double-blind, 2-Arm, Randomized, Phase 2/3, Study of Physician¿s Choice Chemotherapy (PCC) (Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects with Platinum-Resistant, Recurrent, Epithelial Ovarian, Primary Peritoneal or Fallopian Tube CancerOpen
PHXA-15-0002-10-15Can Diet and Physical Activity Modulate Ovarian Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?Open
PHXA-15-0028-80-15A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerOpen